نتایج جستجو برای: gvhd مزمن

تعداد نتایج: 14120  

2009
Jo Nadine Fleming Howard M. Shulman Richard A. Nash Pamela Y. Johnson Thomas N. Wight Allen Gown Stephen M. Schwartz

BACKGROUND The clinical and histologic appearance of fibrosis in cutaneous lesions in chronic graft-versus -host disease (c-GVHD) resembles the appearance of fibrosis in scleroderma (SSc). Recent studies identified distinctive structural changes in the superficial dermal microvasculature and matrix of SSc skin. We compared the dermal microvasculature in human c-GVHD to SSc to determine if c-GVH...

Journal: :Blood 1991
M L Cohn R A Cahill H J Deeg

We investigated in a murine model whether UVB irradiation of lymphohemopoietic cells would prevent the development of graft-versus-host disease (GVHD). Preliminary experiments showed that spleen colony (CFU-S) formation by hemopoietic cells was preserved at UVB doses that eliminated lymphocyte proliferation. In a parent into F1 model, UVB irradiation (5 to 15 mJ/cm2) of spleen cells added to no...

Journal: :Blood 1993
T Nierle D Bunjes R Arnold H Heimpel M Theobald

Recent studies in mice and humans have emphasized an important contribution of host-reactive minor histocompatibility antigen (mH)-specific lymphokine-secreting donor T-helper cells (Th) for the induction of acute graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT). By using limiting dilution (LD) and clonal specificity analyses, we investigated in 14 patients wi...

Journal: :The New England Journal of Medicine 2021

Dipeptidyl peptidase 4 (DPP-4; also known as CD26), a transmembrane receptor expressed on T cells, has costimulatory function in activating cells. In mouse model, down-regulation of CD26 prevented graft-versus-host disease (GVHD) but preserved graft-versus-tumor effects. Whether inhibition DPP-4 with sitagliptin may prevent acute GVHD after allogeneic stem-cell transplantation is not known.

Background:  Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is used as treatment of choice for patients with acute myeloid leukemia (AML). We aimed to evaluate the prognostic factors in 2-year overall survival of patients with non-M3 AML who underwent allogenic HSCT. Methods: This is a Cross sectional retrospective study. Demographic data and study of variables such as age...

Journal: :Blood 2007
Yukimi Sakoda Daigo Hashimoto Shoji Asakura Kengo Takeuchi Mine Harada Mitsune Tanimoto Takanori Teshima

Chronic graft-versus-host disease (GVHD) is the most common cause of poor long-term outcomes after allogeneic bone marrow transplantation (BMT), but the pathophysiology of chronic GVHD still remains poorly understood. We tested the hypothesis that the impaired thymic negative selection of the recipients will permit the emergence of pathogenic T cells that cause chronic GVHD. Lethally irradiated...

Journal: :Blood 2012
Junya Kanda Masakatsu Hishizawa Atae Utsunomiya Shuichi Taniguchi Tetsuya Eto Yukiyoshi Moriuchi Ryuji Tanosaki Fumio Kawano Yasushi Miyazaki Masato Masuda Koji Nagafuji Masamichi Hara Minoko Takanashi Shunro Kai Yoshiko Atsuta Ritsuro Suzuki Takakazu Kawase Keitaro Matsuo Tokiko Nagamura-Inoue Shunichi Kato Hisashi Sakamaki Yasuo Morishima Jun Okamura Tatsuo Ichinohe Takashi Uchiyama

Allogeneic hematopoietic cell transplantation (HCT) is an effective treatment for adult T-cell leukemia (ATL), raising the question about the role of graft-versus-leukemia effect against ATL. In this study, we retrospectively analyzed the effects of acute and chronic graft-versus-host disease (GVHD) on overall survival, disease-associated mortality, and treatment-related mortality among 294 ATL...

Journal: :Blood 2014
Javier Bolaños-Meade Brent R Logan Amin M Alousi Joseph H Antin Kate Barowski Shelly L Carter Steven C Goldstein Elizabeth O Hexner Mary M Horowitz Stephanie J Lee John E Levine Margaret L MacMillan Paul J Martin Adam M Mendizabal Ryotaro Nakamura Marcelo C Pasquini Daniel J Weisdorf Peter Westervelt Vincent T Ho

Corticosteroids are the accepted primary therapy for acute graft-versus-host disease (GVHD), but durable responses are seen in only about half of the patients. Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0802, a phase 3 multicenter randomized double-blinded trial, was designed to test whether mycophenolate mofetil (MMF) plus corticosteroids was superior to corticosteroids alon...

2014
Julia Cromvik Marianne Johnsson Krista Vaht Jan-Erik Johansson Christine Wennerås

While increased numbers of eosinophils may be detected in patients with graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation, it is not known if eosinophils play a role in GVHD. The aims of this study were to determine: whether eosinophils are activated during GVHD; whether the patterns of activation are similar in acute and chronic GVHD; and the ways in which syst...

2014
Shigeo Fuji Markus Kapp Hermann Einsele

Graft-versus-host disease (GVHD) is still one of the major causes of morbidity and mortality in allogeneic hematopoietic stem cell transplantation (HSCT). In the pathogenesis of acute GVHD, it has been established that donor-derived T-cells activated in the recipient play a major role in GVHD in initiation and maintenance within an inflammatory cascade. To reduce the risk of GVHD, intensificati...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید